The sodium phosphate cotransporter family SLC34

Heini Murer, Ian Forster, Jürg Biber, Heini Murer, Ian Forster, Jürg Biber

Abstract

This review summarizes the characteristics of the solute carrier family SLC34 that is represented by the type ll Na/P(i)-cotransporters NaPi-lla (SLC34A1), NaPi-llb (SLC34A2) and NaPi-llc (SLC34A3). Other Na/P(i)-cotransporters are described within the SLC17 and SLC20 families. Type ll Na/P(i)-cotransporters are expressed in several tissues and play a major role in the homeostasis of inorganic phosphate. In kidney and small intestine, type ll Na/P(i)-cotransporters are located at the apical sites of epithelial cells and represent the rate limiting steps for transepithelial movement of phosphate. Physiological and pathophysiological regulation of renal and small intestinal epithelial transport of phosphate occurs through alterations in the abundance of type ll Na/P(i)-cotransporters.

References

    1. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1909-14
    1. N Engl J Med. 2002 Sep 26;347(13):983-91
    1. Am J Physiol. 1999 Apr;276(4 Pt 2):F644-9
    1. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11957-62
    1. Curr Opin Nephrol Hypertens. 2002 Sep;11(5):547-53
    1. Am J Physiol. 1994 May;266(5 Pt 2):F767-74
    1. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14564-9
    1. J Biol Chem. 2002 May 31;277(22):19665-72
    1. Am J Physiol. 1999 Oct;277(4 Pt 1):G756-62
    1. Physiol Rev. 2000 Oct;80(4):1373-409
    1. Am J Physiol. 1998 Jan;274(1 Pt 1):G96-102
    1. Pflugers Arch. 2003 Apr;446(1):52-60
    1. J Clin Invest. 1999 Aug;104(4):483-94
    1. J Biol Chem. 1998 Oct 30;273(44):28568-75
    1. Am J Physiol Regul Integr Comp Physiol. 2001 Feb;280(2):R301-12
    1. Curr Opin Nephrol Hypertens. 2002 Jul;11(4):385-9
    1. Biochem Biophys Res Commun. 1999 May 19;258(3):578-82
    1. Brain Res. 1997 Oct 24;772(1-2):149-55
    1. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5979-83
    1. Am J Physiol. 1995 Jun;268(6 Pt 2):F1017-22
    1. Am J Physiol Renal Physiol. 2002 Apr;282(4):F687-96
    1. Am J Physiol Cell Physiol. 2002 Mar;282(3):C487-93
    1. Am J Physiol. 1999 Nov;277(5 Pt 1):L868-73
    1. Pflugers Arch. 2001 Aug;442(5):782-90
    1. Pflugers Arch. 2002 Jun;444(3):317-26
    1. J Clin Invest. 1997 Aug 1;100(3):538-49
    1. Miner Electrolyte Metab. 1990;16(2-3):115-24
    1. J Biol Chem. 2000 Aug 25;275(34):26113-20
    1. Am J Physiol Cell Physiol. 2001 Mar;280(3):C628-36
    1. Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G426-34
    1. J Biol Chem. 2001 Mar 23;276(12):9206-13
    1. J Biol Chem. 2000 Mar 3;275(9):6284-7
    1. Prog Biophys Mol Biol. 2002 Nov;80(3):69-108
    1. Kidney Int. 1998 Oct;54(4):1224-32
    1. Mol Cell Biol. 2003 Feb;23 (4):1175-80
    1. Am J Physiol Renal Physiol. 2003 Apr;284(4):F663-70
    1. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11470-5
    1. J Membr Biol. 1996 Nov;154(1):1-9
    1. J Cell Biol. 2001 Nov 12;155(4):531-42
    1. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5372-7
    1. Biochem J. 1999 Nov 1;343 Pt 3:705-12

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する